Navigation Links
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Date:9/2/2008

tical chemistry. Dr. LaBarre received his BS degree in Chemistry from Southampton College and his PhD in Bioinorganic Chemistry from the University of Arizona.

James E. Cartoni will oversee various legal matters, including the negotiation and completion of agreements, corporate governance matters, securities compliance, and the coordination and management of outside legal counsel. Prior to joining Halozyme, Mr. Cartoni was a partner at DLA Piper, the world's largest law firm, where he represented numerous public and private companies in areas such as financing transactions, corporate compliance, mergers & acquisitions and general business matters. DLA Piper is Halozyme's primary outside corporate counsel and Mr. Cartoni has represented Halozyme since 2004. Mr. Cartoni also served as the Co-Chair of the Legal and Finance Committee for the 2008 U.S. Open at Torrey Pines Golf Course. Mr. Cartoni obtained his BA degree in Political Science from Occidental College and his Juris Doctor degree from the University of California -- Hastings College of the Law in 1998.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
3. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
7. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
8. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
11. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
(Date:9/18/2014)... -- Health Enhancement Products, Inc. (OTCQB: HEPI), a Michigan ... metabolic processes, is pleased to announce the addition of a ... Nola E. Masterson , a California -based ... 17, 2014. "We,re very pleased and honored ... Andrew Dahl , President and CEO. "She joins us ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... 23 Eisai Corporation of,North America and its ... Food and Drug Administration (FDA) has approved a ... prevention of,chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules ... prevention of acute nausea and,vomiting following initial and ...
... WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and ... in China and the United,States, today announced that ... of Synthetic Chemistry., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Dr. Shuhui Chen, Chief Scientific,Officer of WuXi PharmaTech., ...
... Aug. 22 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: OGXI ... sodium, received Fast Track designation from the U.S. ... for progressive,metastatic prostate cancer. OGX-011 is currently completing ... breast cancer, and is designed to,inhibit the production ...
Cached Biology Technology:FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 3WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... of researchers from McGill University and the Quebec ... polyethylene ,microbeads, Canadian Journal of Fisheries and ... from cosmetics, household cleansers, or industrial cleansers, to ... to their small size and buoyancy, they may ... are a global contaminant in the world,s oceans, ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... press release is available in French . ... are not slower but rather wiser than young brains, which ... according research undertaken at the University Geriatrics Institute of Montreal ... Univeristy of Montreal. "The older brain has experience and knows ...
... important processes during drilling operations. In deepwater drilling, controlling pressure ... the drilled hole can result in blowouts, leading to disastrous ... The deeper the well, the higher the pressure, and the ... drilling, when the pressure applied to balance the hydrocarbon pressure ...
... scientists and collaborators has identified a cellular protein that plays ... online today in separate studies in the journal Nature, ... world,s most deadly viruses. Ebola causes hemorrhagic fever ... humans. The virus is of concern both as a global ...
Cached Biology News:Clinical study shows young brains lack the wisdom of their elders 2A math-based model for deep-water oil drilling 2A math-based model for deep-water oil drilling 3Single protein, key to ebola virus infection, could aid in drug design 2
... Kit #4 detects apoptosis on the ... permeability of cell membranes. This kit contains ... iodide nucleic acid stains. YO-PRO-1 stain selectively ... cells and labels them with moderate green ...
Request Info...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
Biology Products: